TACC2 and neoplasm: Dasatinib administration effectively inhibited the progression of tumors derived from PDX G5824 but only slightly inhibited the progression of tumors derived from PDX G5835 (Fig. 4C-F), indicating that overexpression of PLEKHA1-TACC2 sensitizes tumor cells to dasatinib.